Evaxion Biotech A/S (EVAX) announced new data underscoring the ability of cancer vaccine EVX-01 to drive a targeted and robust immune response. The data demonstrated that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response. EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma.
The company noted that the phase 2 trial investigated EVX-01 in combination with Merck & Co., Inc.'s anti-PD-1 therapy, KEYTRUDA in patients with advanced melanoma. The trial previously yielded strong interim one-year clinical data and remains on track for readout of two-year clinical data in the second half of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.